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ABSTRACT 
HLA-DQ2/8 heterozygous individuals are at far greater risk for type 1 diabetes (T1D) 
development by expressing HLA-DQ8trans on antigen-presenting cells compared to HLA-
DQ2 or DQ8 homozygous individuals. Dendritic cells (DC) initiate and shape adaptive 
immune responses by presenting HLA-epitope complexes to naive T-cells. To dissect the role 
of HLA-DQ8trans in presenting natural islet epitopes, we analyzed the islet peptidome of 
HLA-DQ2, DQ8 and DQ2/8 by pulsing DC with preproinsulin (PPI), IA-2 and GAD65. 
Quality and quantity of islet-epitopes presented by HLA-DQ2/8 differed from DQ2 or DQ8. 
We identified two PPI epitopes solely processed and presented by HLA-DQ2/8 DC; an HLA-
DQ8trans-binding signal-sequence epitope previously identified as CD8 T-cell epitope and a 
second epitope that we previously identified as CD4 T-cell epitope with increased binding to 
HLA-DQ8trans upon posttranslational modification. IA-2 epitopes retrieved from HLA-
DQ2/8 and DQ8 DC bound to HLA-DQ8cis/trans. No GAD65 epitopes were eluted from 
HLA-DQ. T-cell responses were detected against the novel islet-epitopes in blood from T1D 
patients but hardly in healthy donors. We report the first PPI and IA-2 natural epitopes 
presented by highest-risk HLA-DQ8trans. The selective processing and presentation of HLA-
DQ8trans-binding islet-epitopes provides insight in the mechanism of excessive genetic risk 
imposed by HLA-DQ2/8 heterozygosity and may assist immune monitoring of disease 
progression and therapeutic intervention, as well as provide therapeutic targets for 
immunotherapy in subjects at risk for T1D. 
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INTRODUCTION 
Type 1 diabetes (T1D) is an autoimmune disease characterized by autoreactive T-cell 
mediated destruction of the insulin-producing pancreatic beta-cells (1-4). The search for 
naturally processed and presented epitopes (NPPEs) for high-risk HLA class II as target for 
autoreactive CD4 T cells in T1D has been focus of attention over the years. Most attention 
was given to HLA-DR binding epitopes (5, 6), whereas HLA-DQ binding epitopes deserve 
investigation, too. Indeed, subject heterozygous for HLA-DQ2 and -DQ8 are endorsed with 
by far the highest risk for development T1D, but it remains unclear what functional 
consequences explain this synergistically increased risk compared to a double dose of HLA-
DQ2 or -DQ8. We previously revealed the unique peptide binding properties of HLA-DQ 
molecules composed of the products of DQA1*0201 (coding for the alpha chain of DQ2) and 
DQB1*0302 (coding for the beta-chain of DQ8), the so-called HLA-DQ8trans molecule (7-
9). The islet epitopes presented by HLA-DQ8trans are largely unknown. Importantly, 
DQ8cis/trans-restricted CD4 T cell clones have been isolated from human insulitis lesions 
and T cell autoreactivity was confirmed for several pro-insulin peptides, underscoring the 
potential relevance of PPI peptides presented by HLA-DQ in diabetogenesis (10-13). We 
contend that knowledge of the HLA-DQ8trans islet peptidome provides insight in the 
mechanism by which HLA-DQ2/8 heterozygosity imposes excessive risk for T1D. In turn, 
HLA-DQ-restricted islet epitopes could yield key reagents for biomarker assays (ELISPOT, 
DQ tetramers) and feed the pipeline of islet tissue specific reagents being developed for 
peptide immunotherapy (8, 14-16). 
Islet-epitopes for T1D predisposing HLA class II molecules have been identified by in silico 
prediction of T cell epitopes (17-19), using overlapping islet-peptides (14, 15, 20-22) or by 
pulsing B-cells with islet-antigens (23, 24). Although these approaches can identify CD4 T 
cell epitopes, epitopes derived from islet-autoantigens are generally presented by HLA class 
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II molecules after a sequence of events termed naturally processing and presentation by 
professional antigen-presenting cells APC (25). Dendritic cells (DC) are the master regulators 
of the immune orchestra and initiate and shape both the innate and adaptive immune 
responses. Here, we investigated presentation of islet-epitopes by DC expressing T1D 
highest-risk HLA-DQ. For this purpose, HLA-DQ2 and/or DQ8 expressing DC were pulsed 
with three islet-autoantigens, namely preproinsulin (PPI), islet tyrosine phosphatase IA-2 
(insulinoma-associated antigen-2) and glutamic acid decarboxylase (65 kDa isoform; 
GAD65). After HLA-DQ isolation and peptide elution, using an HLA-elution method that we 
optimized for low cell numbers, eluted NPPE were analyzed using high-resolution tandem 
mass spectrometry. To verify the relevance of these peptides derived from the islet-
autoantigens in the context of T1D immunopathology, we analyzed peripheral blood of HLA- 
and age-matched T1D patients and non-diabetic patients for the presence of autoreactive T 
cells. We report the first islet-epitopes that are uniquely processed and presented by the T1D 
highest-risk HLA-DQ2/8 molecules expressed on DC. These islet-epitopes are preferentially 
presented by HLA-DQ8trans. Such novel HLA-DQ restricted epitopes can be used as 
biomarkers for disease progression and/or contribute to the development of novel 
immunotherapeutic strategies (e.g. tolerogenic dendritic cell therapy). 
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RESEARCH DESIGN AND METHODS 
Blood donors. After informed consent, peripheral blood was drawn from patients diagnosed 
with T1D (n=30, age: 17±6; disease duration ranging from 0 to 43 years) and from age and 
HLA-DQ matched healthy controls (n=36, age: 27±6). Peripheral blood mononuclear cells 
(PBMC) were freshly isolated by Ficoll centrifugation and resuspended in culture medium 
(Iscove’s modified Dulbecco medium (Gibco BRL, Paisely, UK) containing 10% pooled 
human, heat inactivated serum. PBMC were subsequently tested for the presence of 
autoreactive CD4 T cells using ELISPOT. 
 
Proteins and peptides. Recombinant proteins were produced as previously described (26). 
Briefly, PPI, IA-2 and GAD65 were amplified by PCR from human islet cDNA. PCR 
products were cloned by Gateway technology (Invitrogen, Carlsbad, CA) in a bacterial 
expression vector containing a histidine tag at the N-terminus. Proteins were overexpressed in 
Escherichia coli BL21(DE3) and affinity purified using anti-His antibody (Invitrogen, 
Carlsbad, CA). Size and purity of recombinant proteins were analyzed by gel electrophoresis 
and Western blotting using anti-His antibody. Endotoxin contents were below 50 IU/mg 
recombinant protein which is below the detection threshold, as tested using a Limulus 
Amebocyte Lysate (LAL) assay (Cambrex, East Rutherford, NJ). All proteins were tested in 
lymphocyte stimulation assays in order to exclude antigen-nonspecific T-cell stimulation. 
Peptides were synthesized according to standard fluorenylmethoxycarbonyl (Fmoc) 
chemistry using a SyroII peptide synthesizer (MultiSynTech, Witten, Germany). The 
integrity of the peptides was checked using UPLC-MS and Maldi-Tof MS. The following 
biotinylated indicator peptides were used in the cell-free HLA-DQ peptide binding studies: 
CLIP: KMRMATPLLMQAL (DQ2cis); AAEAALEAEEWAA (DQ2trans); 
AAPHTTQPAVEAA (DQ8trans); HSV-2: EEVDMTPADALDDFD (DQ8cis).  
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Generation of dendritic cells. Isolation and generation of DC from homozygous HLA-DQ2, 
homozygous HLA-DQ8 or heterozygous HLA-DQ2/8 healthy blood donors was performed 
as described previously (27). PBMC isolated from each buffy coat were separately cultured 
and pulsed with islet antigens. For each elution a total of 40x106 pulsed mDCs were obtained 
from three donors per HLA-DQ genotype that were pooled after pulsing with islet 
autoantigen prior to the HLA-peptide elutions. PBMC were isolated by Ficoll gradient from 
three HLA-typed buffy coats per HLA-DQ typing and subsequently CD14+ monocytes were 
isolated and cultivated with GM-CSF (800 U/ml) and IL-4 (500 U/ml) (Invitrogen, Breda, 
The Netherlands) for 6 days to obtain immature DC (iDC). The iDCs were pulsed with PPI, 
IA-2 and GAD65 for 6 hrs after which iDC were matured by incubating 0.5×10
6
 DCs/well in 
a 24 well plate with LPS (100ng/mL) for 24 hrs in the continuous presence of the three islet-
autoantigens. After 30 hrs pulsed mDC were harvested, washed three times with PBS to 
remove excess of islet-autoantigens and lysed in 1mL lysis buffer (50mM Tris, 150mM 
NaCl, 5mM EDTA, 0.5% zwitterion, 10mM iodoacetamide and protease inhibitors (complete 
inhibitor mix, Roche)) and subsequently high-speed centrifuged for 60min at 10,000 x g to 
remove nuclei and insoluble material.  
 
Proteome analysis of dendritic cells pulsed with islet-autoantigens. Islet autoantigens 
pulsed mDC were lysed and proteins were digested using the filter aided sample preparation 
(FASP) method (28). Briefly, 100μg of protein was loaded on a 30kDa filter. SDS was 
removed in three washes by 8M urea. The proteins were alkylated using iodoacetamide, and 
the excess reagent was washed through the filters by three additional washes with 8M urea. 
Proteins were overnight digested using endoproteinase LysC (endoLysC) followed by a four 
hour digestion using trypsin at room temperature. Tryptic peptides were desalted on C18 
SepPak. Peptides were subsequently fractionated by SCX on an Agilent 1100 system 
7 
 
equipped with an in-house packed SCX-column (320µm ID, 15cm, polysulfoethyl A 3μm, 
Poly LC), run at 4μl/min. The gradient started with 10min at 100% solvent A 70/30/0.1 
(water/acetonitrile/formic acid), after which a linear gradient was started to reach 100% 
solvent B (250mM KCl, 35% acetonitrile. 0.1% formic acid) in 15min, followed by 100% 
solvent C (500mM KCl, 35% acetonitrile 0.1% formic acid) in the following 15min. The 
eluent was held at 100% solvent C for 5 minutes to clean the column, then switched back to 
100% solvent A. 15 fractions were collected in 1min intervals, lyophilized and reconstituted 
in 30μl 95/3/0.1 (water/acetonitrile/formic acid). Dissolved fractions were analyzed by on-
line nano-HPLC MS with a system, consisting of an Agilent 1100 gradient HPLC system 
(Agilent, Waldbronn, Germany) and a LTQ-FT Ultra mass spectrometer (Thermo, Bremen, 
Germany). Fractions (5μl) were injected onto a home-made precolumn (100μm×15mm; 
Reprosil-Pur C18-AQ 3µm, Dr. Maisch, Ammerbuch, Germany) and eluted via a home-made 
analytical nano-HPLC column (15cm×50µm; Reprosil-Pur C18-AQ 3μm). The gradient was 
run from 0% to 30% solvent B (10/90/0.1 water/acetonitrile/formic acid) in 10-155min. A tip 
of approximately 5µm was drawn from the tip of the nano-HPLC column to act as 
electrospray needle. Full scan mass spectra were acquired in the FT-MS with a resolution of 
25,000 at a target value of 5*10
6
. The five most intense ions were selected and fragmented in 
the linear ion trap using collision-induced dissociation at a target value of 10,000. For MS2 
spectral matching Mascot 2.2.04 (Matrix Science) was used, with 2 ppm precursor and 0.5 Da 
fragment accuracy. Variable modifications included N-terminal protein acetylation and 
methionine oxidation. Carbamidomethylation of cysteine was selected as a fixed 
modification. False discovery rate was set to 1%. 
 
Peptide elution and isolation from affinity-purified HLA-DQ. Affinity-purification of 
HLA-DQ molecules from mDC and subsequent peptide elutions were performed as follows. 
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We optimized our existing peptide elution protocol (8) for low DC numbers. All HLA-DQ 
isolation and washing steps were performed using a 100µL pipet tip. Lysate was precleared 
by running it through a 100µL pipet tip containing a small filter and packed with 100µL 
Sepharose beads. The precleared lysate was collected and HLA-DQ molecules were 
subsequently isolated using a pan-DQ (SPV-L3) antibody coupled to Sepharose beads and 
packed in a 100µL pipet tip; the lysate was passed through the SPV-L3 microcolumn to 
isolate HLA-DQ molecules by gravity force. Columns were washed with four bed volumes 
lysis buffer, subsequently followed by four bed volumes low salt buffer (120mM NaCl, 
20mM Tris-HCl, pH 8.0), high salt buffer (1M NaCl, 20mM Tris-HCl, pH 8.0), no salt buffer 
(20mM Tris-HCl, pH 8.0) and low Tris buffer (10mM Tris-HCl, pH 8.0). The HLA-peptide 
complexes were eluted with two bed volumes 10% acetic acid.  HLA-DQ eluates (containing 
both peptides and HLA) were fractionated with an HPLC system. The material was eluted 
using a gradient of 0-50% acetonitrile supplemented with 0.1% trifluoroacetic acid. 
 
Peptide identification by mass spectrometry. Mass spectrometry analysis of HLA eluted 
peptides was performed as described previously (8) with some modifications. After immune 
precipitation, proteins and HLA-peptides in the unfiltered eluate were separated by selective 
elution from a small C18-column in two fractions with 20% and 30% acetonitrile, 
respectively (29). Subsequently the HLA-peptides were analysed via on-line C18-nano-
HPLC-MS with a system consisting of an Easy nLC 1000 gradient HPLC system (Thermo, 
Bremen, Germany), and a Q-Exactive mass spectrometer (Thermo). Fractions were injected 
onto a homemade precolumn (100μm×15mm; Reprosil-Pur C18-AQ 3μm, Dr. Maisch, 
Ammerbuch, Germany) and eluted via a homemade analytical nano-HPLC column 
(15cm×50μm; Reprosil-Pur C18-AQ 3μm). The gradient was run from 0% to 30% solvent B 
(10/90/0.1 water/ACN/FA) in 120 min. The nano-HPLC column was drawn to a tip of ∼5μm 
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and acted as the electrospray needle of the MS source. The Q-Exactive mass spectrometer 
was operated in top10-mode. Parameters were resolution 70,000 at an automatic gain control 
(AGC) target value of 3 million maximum fill time of 100ms (full scan), and resolution 
35,000 at an AGC target value of 1 million/maximum fill time of 128ms for MS/MS at an 
intensity threshold of 78,500. Apex trigger was set to 1 to 5 seconds, and allowed charges 
were 1-3. In a post-analysis process, raw data were converted to peak lists using Proteome 
Discoverer 1.4. For peptide identification, MS/MS spectra were submitted to the human IPI 
3.87 database using Mascot Version 2.2.04 (Matrix Science) with the following settings: 
10ppm and 20 millimass units (mmu) deviation for precursor and fragment masses, 
respectively; no enzyme was specified. All reported hits were assessed manually. 
 
Cell free HLA-DQ/peptide binding assays. Binding of identified islet-peptides to all four 
HLA-DQ molecules was studied in cell-free HLA-DQ peptide binding assays. As source of 
HLA-DQ, EBV-BLCL cells lentiviral transduced to express a single HLA-DQ molecule were 
used (8). These assays are based upon competition between a fixed concentration biotinylated 
reporter peptide (0.6µM) and an unbiotinylated islet-peptide (0-300µM); once the islet 
peptide competes with the indicator peptide a drop in signal (counts per minute; CPM) is 
observed representing binding of the islet-peptide. Affinities are subsequently calculated 
using GraphPad software (version 5); the concentration of islet-peptide required for half-
maximal inhibition of binding of the reporter peptide indicate the EC50 value. Although 
binding of the islet-peptides to different HLA-DQ molecules cannot be compare accurately 
due to amino acid sequence of indicator peptides differing between the HLA-DQ assays, 
different HLA-DQ molecules with different properties), a difference in EC50 value  10 times 
was considered substantial. 
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Detection of DQ naturally processed and presented epitopes specific IFN- and IL-10 
secreting CD4 T-cells. Detection of IFN- and IL-10 production by CD4 T-cells in response 
to the identified NPPE (10µg/mL) was performed using an enzyme-linked immunospot 
(ELISPOT) as described previously (30). Data are expressed as the total number of spots per 
triplicate divided by the total number of spots in triplicate in the presence of diluent alone 
(=SI). Stimulation index (SI)  3 are considered as positive. 
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RESULTS 
Uptake of islet antigens by pulsed dendritic cells. Since our islet-antigens were not labeled 
with a fluorescent dye and antigen uptake and processing cannot be measured by 
flowcytometry or fluorescent microscopy, we performed proteome analysis of DC pulsed 
with PPI, IA-2 and GAD65 to confer intracellular uptake of the islet antigens. Lysates of 
islet-antigen pulsed mDC (40x106) were digested with trypsin and tryptic peptides were 
analyzed by MS. Identified peptides were screened against a human protein database 
containing the amino acid sequences of PPI, IA-2 and GAD65. We independently analyzed 
the proteome of two lysates pulsed with PPI/IA-2/GAD65. Of all three islet-antigens we 
retrieved peptides derived from the antigens in the two lysates. Peptides of both the N- and C-
terminus were identified in two independent proteome analysis covering 32.0±0% of PPI, 
23.0±1.0% of GAD65 and 26.5±0.5% of IA-2 (Supplemental Figure 1). In addition, nested 
sets of peptides were retrieved, indicating accurate MS analysis. These data show that islet-
antigen pulsed mDC efficiently take up whole antigens. 
 
Identification of peptides eluted from highest-risk HLA-DQ2/8 and HLA-DQ8. To 
decipher the HLA-DQ islet-peptidome, immature DC homozygous for HLA-DQ2 or HLA- 
DQ8 or heterozygous for HLA-DQ2/8 were pulsed with PPI, IA-2 and GAD65 and 
subsequently matured with LPS and IFN-. Complete maturation of DC was confirmed by 
phenotype (not shown). A total of 353 unique peptides (derived from 56 proteins) were eluted 
from HLA-DQ2/8. In total, more islet-peptides were retrieved from heterozygous HLA-
DQ2/8 (19/353; 5.4%) compared to homozygous HLA-DQ8 DC (6/459; 1.3%). From DQ2 
no islet peptides were eluted. PPI and IA-2 peptides were retrieved from HLA-DQ2/8 and 
HLA-DQ8. GAD65 islet-peptides were not identified. From PPI, peptides with a mean length 
of 13 amino acids (range 8-16) were retrieved solely from DC expressing the highest-risk 
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HLA-DQ2/8 molecules (Figure 1 and Table 1). In total, three PPI peptides were eluted from 
HLA-DQ2/8 encompassing two distinct core-regions: PPI17-24 (part of the PPI signal-
sequence) and PPI54-69. Intriguingly, PPI17-24 has been identified as a CD8 T cell epitope that 
is naturally processed and presented by HLA-A2 (31). Now, for the first time PPI17-24 is 
identified as a naturally processed and HLA-DQ presented peptide. Recently, we identified 
PPI54-69 (TRREAEDLQVGQVELG) as a CD4 T cell epitope that preferentially is presented 
by HLA-DQ8trans and becoming highly immunogenic after posttranslational modification 
(30). Here, this same PPI54-69 epitope is naturally processed and presented by heterozygous 
HLA-DQ2/8 expressing DC. Peptides from the C-terminus of PPI were not retrieved.  
From HLA-DQ2/8 a total of 16 IA-2 peptides (Figure 1 and Table 1) were eluted with a 
mean peptide-length of 14 amino acids (range 11-19). All peptides are members of nested 
peptide sets covering three distinct core-regions of the N-terminus of IA-2. Similar nested 
peptide sets were retrieved from HLA-DQ8. Peptides from the C-terminus of IA-2 were not 
retrieved. To validate MS analysis of the identified peptides, we synthesized PPI and IA-2 
eluted peptides (PPI17-24, IA-2296-311 and IA-2319-333); MS spectra of the eluted peptides and 
the synthesized peptides fully overlapped (Supplemental Figure 2).  
 
Binding of identified eluted PPI and IA-2 peptides to HLA-DQ. HLA-DQ2/8 
heterozygous cells can express four types of HLA-DQ molecules: HLA-DQ2cis, HLA-
DQ2trans, HLA-DQ8trans and HLA-DQ8cis (11). Therefore, HLA-DQ binding of the PPI 
and IA-2 eluted peptides was validated in competitive HLA-DQ/peptide binding assays. 
Binding of PPI54-69 to HLA-DQ was already validated in our previous study (30). PPI17-24 
only bound to HLA-DQ8trans (Figure 2 and Table 1). IA-2 peptides, encompassing the same 
core-regions, were retrieved from HLA-DQ2/8 and HLA-DQ8. Binding of IA-2142-159, IA-
2293-311 and IA-2318-333 was observed for HLA-DQ8trans and -DQ8cis (Figure 3 and Table 1). 
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Strong binding of these IA-2 peptides was observed for HLA-DQ8trans and weak binding for 
HLA-DQ8cis. Binding of the IA-2 eluted peptides to HLA-DQ2cis/trans was not observed.  
 
Identification of the minimal HLA-DQ-binding registers. The minimal binder registers 
(MBR) in the eluted peptides responsible for HLA-DQ binding, were in silico predicted by 
employing the predictions algorithm software MOTIFS and the peptide-binding motifs of all 
four HLA-DQ molecules (8). Predicted MBR in the IA-2 peptides for HLA-DQ8cis/trans 
(Table 1) were consistent with the observed binding of the eluted IA-2 peptides to HLA-
DQ8cis/trans. MBR in the eluted IA-2 peptides for HLA-DQ2cis/trans were not predicted. 
The majority of eluted IA-2 peptides contained three to four anchor residues (crucial for 
HLA-peptide binding; in bold) in the predicted MBR for HLA-DQ8trans (black) and two 
anchor residues for HLA-DQ8cis (gray). Indeed, stronger binding of the IA-2 peptides to 
HLA-DQ8trans was observed compared to HLA-DQ8cis. To validate HLA-DQ binding of 
the putative registers in the IA-2 peptides, synthetic peptides spanning the MBR (underlined 
in Table 1) were synthesized with two extra alanines both N- and C-terminally necessary for 
proper HLA-DQ binding. Strong binding to DQ8trans was observed for five predicted 
DQ8trans registers and two predicted DQ8cis registers bound with low affinity to DQ8cis 
(data not shown). These in silico predictions support the results from the DQ elution studies; 
number of eluted IA-2 peptides DQ8trans  DQ8cis.  
 
Cytokine responses of T1D patients and healthy controls with naturally processed and 
presented islet peptides eluted from high-risk HLA-DQ. We examined proliferative 
responses in fresh peripheral blood of T1D patients and HLA-DQ and age matched non-T1D 
control subjects against the DQ NPPEs derived from PPI and IA-2 using ELISPOT. 
ELISPOT studies with T1D patients and the identified PPI54-69 natural epitope was already 
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performed previously (30). Collectively, T-cell responses in T1D patients could be observed 
against three DQ naturally epitopes ex vivo in 12/30 (40%) for PPI17-24, 16/30 T1D patients 
(53%) for IA-2293-311 and 16/30 (53%) for IA-2318-333 (Figure 3 and Supplemental Tables 1 
and 2). Only few patients (2/21; 9.5%) responded to IA-2142-159 by producing IL-10 (not 
shown). Healthy individuals showed less frequent responses to the tested DQ natural epitopes 
(15-28%) with the majority of healthy individuals responding with IFN- to PPI17-24 and with 
IL-10 to the IA-2 epitopes. Patients responding to PPI17-24 produced IFN-γ (31%), IFN-γ+IL-
10 (8%) or IL-10 (61%). As we recently reported that the PPI17-24 epitope is also presented by 
HLA-A2 to autoreactive CD8 T cells (31) we checked the HLA class I typing when available, 
but we did not see a trend in that direction; all five cases in which PBMC from patients 
responded to PPI17-24 by production of IFN- were HLA-A2 negative. This excludes the 
possibility that this responsiveness can be attributed to HLA-A2 restricted CD8 T cells.  
Patients showed predominantly IFN-γ to the two IA-2 epitopes (75% and 88%, respectively); 
patients responding to IA-2293-311 produced IFN-γ (62.5%) or IFN-γ+IL-10 (12.5%) and 25% 
patients responded solely with IL-10. Patient responses against IA-2318-333 showed even a 
more proinflammatory phenotype as 75% produced IFN-γ and 12.5% produced IFN-γ+IL-10. 
A decrease in patients responding to IA-2318-333 exclusively with IL-10 (12.5%) was observed 
as compared to IA-2293-311. Our data demonstrate that autoreactive CD4 T cell responses can 
be detected against these novel PPI and IA-2 naturally epitopes that preferentially bind the 
T1D highest-risk HLA-DQ8trans molecule. Furthermore, both the quality and prevalence of 
these T-cell responses differ between T1D patients and non-T1D case controls. While our 
cohort remains insufficiently sized to draw firm conclusions regarding the influence of HLA 
status on the presence of CD4 T-cell responses, these data demonstrate the presence of 
autoreactive T cell responses against the identified novel DQ epitopes. 
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DISCUSSION 
We provide evidence on the functional consequences of presentation of islet-proteins by the 
highest-risk HLA-DQ8trans that may contribute to the association of this molecule with the 
highest genetic predisposition to T1D. Both qualitative and quantitative differences are 
observed between the islet peptidomes of HLA-DQ2/8 heterozygosity versus homozygosity. 
First, the total number of peptides derived from PPI and IA-2 presented by highest-risk HLA-
DQ2/8 is greater compared to homozygous HLA-DQ8, whereas no islet peptides were 
retrieved from homozygous HLA-DQ2. Second, HLA-DQ2/8 DC generate an exclusive islet 
peptidome uniquely presented by the highest-risk HLA-DQ8trans molecule. Finally, we 
provide evidence that DC selectively present islet autoantigens PPI and IA-2 epitopes but not 
GAD65 epitopes by high-risk HLA-DQ.   
The identified PPI naturally processed peptides were retrieved solely from highest-risk HLA-
DQ2/8 were confirmed to bind HLA-DQ8cis/trans selectively. The unusually short DQ 
binding PPI17-24 peptide is located in the signal-sequence of PPI and has been described as a 
naturally processed and HLA-A2 restricted epitope of diabetogenic CD8 T cells (31). We 
now report islet autoreactive CD4 T cell responses against the same PPI epitope in T1D 
patients, but not healthy age and HLA matched subjects. The PPI17-24 epitope as an 8-mer 
does not fulfill the high-risk HLA-DQ peptide-binding motif (8). Yet, binding of PPI17-24 was 
confirmed for HLA-DQ8trans. Unconventional length and binding of peptides to HLA class 
II molecules has been reported (32, 33). Our finding that PPI17-24 as an 8-mer is naturally 
presented by T1D highest-risk HLA-DQ8trans extends the notion that CD4 T cells can 
respond to unusually presented self-peptides. This signal peptide was generated by DC pulsed  
with whole PPI. The question that emerged is how peptides from the signal-sequence of PPI 
can be presented by HLA-DQ on DC. In the NOD mouse model of autoimmune diabetes, 
insulin-secretory granules from beta-cells and even whole beta-cells are ingested by APC and 
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transported to the pancreatic lymph node (34, 35) and T cells from T1D patients respond to 
beta-cell derived insulin secretory granules (36). Subsequently, intact or partially synthesized 
PPI that is embedded in the ER can become a natural source of signal peptides presented by 
HLA-DQ8trans on the surface of DC. Pancreatic beta-cells do not secrete whole PPI as 
extracellular source for uptake by DC. However, a small proportion of whole PPI (including 
the signal sequence) is present in the cytosol of human islets that may become accessible to 
DC under pathological conditions in T1D such as beta-cell stress, thus ending up in HLA-DQ 
for presentation to the immune system (37, 38). We previously reported PPI54-69 as 
preferentially presented by the highest-risk HLA-DQ8trans molecule (30). The proportion of 
patients responding against this epitope doubled after posttranslational modification, with the 
majority of patients showing a proinflammatory immune response. This PPI54-69 epitope is 
now confirmed as processing product presented solely by HLA-DQ2/8 heterozygous DC. 
IA-2 peptides were presented both by HLA-DQ2/8 and to a lesser extent HLA-DQ8 
expressing DC and encompassed identical core-regions that were derived solely from the IA-
2 extracellular domain. Binding of the IA-2 peptides was validated for HLA-DQ8cis/trans. 
As humoral responses have been detected against the IA-2 intracellular domain, several 
immune studies hitherto focused on CD4 T cell epitopes derived from the IA-2 intracellular 
domain. Uptake of IA-2 by pulsed DC was confirmed but peptides from the IA-2 intracellular 
domain were not retrieved, which may imply a limited relevance of these peptides as target 
for CD4 T cells in the context of high-risk HLA-DQ. Preliminary data show that, peptides 
from the IA-2 extracellular domain were retrieved derived solely from DQ2/8 heterozygous 
DC that were deamidated at one Q residue, suggesting  posttranslational modification of islet-
peptides presented by highest-risk DQ2/8 expressed on DC. 
The  naturally processed PPI and IA-2 epitopes identified approved to be targets of CD4 T 
cells in approximately half of the T1D patients. Patient T cells responding to the IA-2 
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epitopes showed a proinflammatory phenotype (IFN-), whereas the IA-2 specific T cells 
from few responding non-diabetic donors showed an anti-inflammatory response (IL-10). 
Intriguingly, immune responses to PPI17-24 showed an inverse pattern of cytokine production 
that we speculate to reflect differential regulatory mechanisms against different islet epitopes 
in T1D patients versus healthy donors. T-cell responses to peptides eluded from HLA-DQ2/8 
DCs were not exclusively recognized by HLA-DQ2/8 heterozygous T1D patients. While it is 
certainly conceivable that other HLA molecules than those tested here may act as alternative 
restriction element in such cases (notably HLA-A2) (31), this discrepancy between the HLA-
DQ ligandome generated by processing of the whole PPI protein versus exogenous pulsing 
with an excess of synthetic PPI peptide only in the T-cell assay may also relate to the notion 
that the amount of PPI peptides in the latter case may overcome the threshold required for T-
cell activation in T1D donors expressing either DQ2 or DQ8. This peptide was repeatedly 
undetectable in elution studies from DQ2 or DQ8 homozygous donors, but exclusively 
retrieved from HLA-DQ2/8 heterozygous DCs upon processing of PPI protein. Yet, our 
HLA-DQ binding studied demonstrate that once a peptide is generated, it may also bind to 
other HLA-DQ molecules, be it to a lesser extent. 
GAD65 peptides were not retrieved from HLA-DQ, although uptake of the protein was 
confirmed by proteome analysis of pulsed DC. Peptide loading pathways in APC are diverse; 
peptide loading into HLA class II molecules in the MHC class II compartment requires CLIP 
derived from the invariant chain and HLA-DM for presentation in DC, but in B-cells a 
modifier of HLA-DM is expressed (HLA-DO) that associates with HLA-DM and restricts 
HLA-DM activity to more acidic compartments in B-cells. Although the exact role of HLA-
DO in different APCs remains largely unknown, DO can function as a competitive and 
irreversible inhibitor of HLA-DM in subsets of APCs (39, 40); when present, DO subtly 
alters the repertoire of HLA class II-bound peptides displayed at the surface of APCs. DO is 
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mainly expressed in B-cells and its effect on HLA class II presentation would therefore be 
mostly observed in B-cells. Epitopes recognized in the context of DQ display a DM-sensitive 
phenotype, whereas for DR molecules a tendency towards DM-resistant epitopes is observed 
(41); presentation of DM-sensitive (DQ) antigens benefited more from maturation of DCs 
compared with DM-resistant (DR) antigens. Thus peptide binding to HLA class II molecules 
is modulated differently in B-cells compared to DC providing a plausible explanation why 
DC do not present GAD65 peptides in HLA-DQ. Since GAD65 epitopes have been identified 
to be naturally processed and presented by B-cells as target of CD4 T cells, this implies that 
DC, uniquely involved in priming of naïve CD4 T cells, present a relative small set of islet-
epitopes in HLA-DQ to autoreactive T cells derived from a limited number of islet 
autoantigens.  
The recombinant islet proteins used in this study are not necessarily in their native 
conformation. For dendritic cells (DCs) the 3D-structure is not crucial for protein uptake. 
This may differ for B-cells, for which the 3D-structure of an antigen is important for uptake 
via the B-cell receptor and subsequent processing. For identification of B-cell epitopes, 
proper folding of the recombinant proteins will therefore be more important. Nonetheless, the 
actual processing occurs in lysozymes, in which the acidic milieu will affect the natural 
confirmation of proteins. Considering the time of antigen processing that we elected, the 
possibility remains that additional peptides may generated and presented by DCs. Studies in 
mice show that DCs are able to retain and present antigens long after uptake (42) and that the 
same peptides are presented by DC at early and later time points. Rapidly generated peptides 
from proximal parts of antigens may be over-represented in our approach. It is conceivable 
that additional peptides presented by (subsets of) DCs at later time points after uptake in vivo 
may arise.  
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It is conceivable that our identified PPI and IA-2 DQ-NPPEs represent the tip of the iceberg 
of the total islet peptide ligandome. The identified peptides in this study might impose a bias 
regarding most favorable binding characteristics and peptides having unfavorable properties 
are more challenging to identify due to technical limitations. Nevertheless, our observations 
that the particular islets eluted from HLA-DQ proved immunogenic in T1D patients in 
particular compared to non-diabetic subjects, even if their binding affinity to HLA was 
relatively weak, implies that our strategy of epitope discovery with potential relevance to the 
disease is suitable and rewarding. 
Our identification of naturally processed and HLA-DQ presented epitopes by DC may bear 
relevance to the selection of islet peptides for prevention of T1D to avoid loss of tolerance to 
the triggering epitopes, impacting the choice of potential therapeutic agents for the prevention 
of T1D, as well as immune monitoring of islet autoreactive CD4 T-cell responses in  
prediction, disease progression and possibly as surrogate end-points in immunotherapeutic 
trials and as part of the developing area of HLA-DQ tetramer technology in T1D. 
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LEGENDS 
 
FIGURE 1. PPI and IA-2 peptides eluted from high-risk HLA-DQ2/8 and HLA-DQ8. 
HLA-DQ2 or HLA-DQ8 homozygous and HLA-DQ2/8 heterozygous DC were pulsed for 6 
hours with islet-autoantigens PPI, GAD65 and IA-2 after which the cells were matured for 
24hrs with LPS and IFN- in the continuous presence of the islet-autoantigens. After cell 
lysis, HLA-DQ was purified using SPV-L3 (pan-DQ antibody) and peptides were acid eluted 
and analyzed by mass spectrometry. Nested sets of peptides, covering distinct core-regions of 
PPI and IA-2 were eluted. 
 
FIGURE 2. Binding validation of identified HLA-DQ eluted peptides from PPI and IA-
2. Binding of eluted PPI17-24 (black) and PPI54-69 (gray) peptides and the three longest 
peptides representing the three distinct core regions of IA-2 (IA-2142-159: soft gray; IA-2293-311: 
light gray; IA-2318-333: dark gray), were tested in competitive peptide-binding assays for 
binding to HLA-DQ2cis, -DQ2trans, -DQ8trans and -DQ8cis.  Data represent mean ± SEM 
(n=3). Shown on the x-axes is 1/EC50, thereby illustrating that large bars represent better 
binding.  
 
FIGURE 3. Cytokine responses of T1D patients and healthy controls against PPI and 
IA-2 naturally epitopes eluted from high-risk HLA-DQ.  PPI17-24 and IA-2 naturally 
peptides (core 1: IA-2142-159; core 2: IA-2293-311 and core 3: IA-2318-333) eluted from high-risk 
HLA-DQ were tested for immune responses in T1D patients (n=30) and healthy controls 
matched for age and high-risk HLA-DQ (n=36). Responses against IA-2142-159 were observed 
in 2/21 T1D patients (not shown). Patient and control cytokine responses (IFN- versus IL-
10) against PPI17-24 (green circles), IA-2293-311 (blue circles) and IA-2318-333 (red circles) are 
viewed in two separate dotplots. An overview of the quality of the immune responses against 
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the three natural epitopes is viewed in separate pie charts and are indicated as 
proinflammatory (IFN-; black), regulatory (IL-10; soft gray) or a combination of both (light 
gray).  
 
TABLE 1. Experimentally observed masses of PPI and IA-2 peptides eluted from 
highest-risk HLA-DQ2/8. Alignments of naturally processed peptides derived from islet-
autoantigens presented by T1D high-risk HLA-DQ2/8. Residues in bold represent the anchor 
residues in the predicted minimal binding cores of the naturally epitopes for HLA-DQ8trans 
(black) and HLA-DQ8cis (gray). Minimal 9-mer binding registers (MBR) for HLA-
DQ8cis/trans are underlined. HLA-DQ2cis/trans MBR were not predicted. Shown are the 
EC50 values of the longest eluted peptides from HLA-DQ8trans and -DQ8cis as validated by 
HLA-peptide binding studies. 
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TABLE 1. Experimentally observed masses of PPI and IA-2 peptides eluted from 
highest-risk HLA-DQ2/8. 
Observed 
m/z 
Calculated m/z Residues 
Corresponding 
protein sequence 
        IC50 (µM)  
DQ8trans   DQ8cis 
   PPI 
   core 1    
      784.36   783.35  17-24 WGPDPAAA 0.3±0.01 nb 
   core 2    
      600.64   1798.92  54-69 TRREAEDLQVGQVELG 
 16±2 (26)  64±8  
(ref 26) 
      566.96   1697.87  55-69  RREAEDLQVGQVELG   
   IA-2 
   core 1    
634.00 1899.00 142-159  LQDIPTGSAPAAQHRLPQ 17.7±3.3 29.2±5.9 
591.31 1770.94 142-158 LQDIPTGSAPAAQHRLP       
   core 2    
647.64 1939.92 293-311   VPRLPEQGSSSRAEDSPEG 13.0±0.1 68.6±44.5 
580.78 1159.55 296-306 LPEQGSSSRAE       
638.29 1274.57 296-307  LPEQGSSSRAED    
681.81 1361.61 296-308   LPEQGSSSRAEDS        
794.85 1587.70 296-310     LPEQGSSSRAEDSPE   
823.36 1644.72 297-311      LPEQGSSSRAEDSPEG   
738.31 1474.62 297-310      PEQGSSSRAEDSPE   
766.83 1531.65 297-311       PEQGSSSRAEDSPEG   
718.29 1434.59 298-311        EQGSSSRAEDSPEG   
   core 3    
508.58 1522.74 318-333  GDRGEKPASPAVQPDA  5.2±0.6 57.6±7.0 
733.86 1465.71 319-333   DRGEKPASPAVQPDA       
489.57 1465.72 319-332  DRGEKPASPAVQPD    
451.23 1350.69 320-332   RGEKPASPAVQPD       
598.30 1194.59 321-332    GEKPASPAVQPD   
D
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